Low-Cost Contingency Management for Hispanic Outpatients - 3

Substance Abuse Clinical Trial

Official title:

Low-Cost Contingency Management for Hispanic Outpatients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00249548
• Other study ID #: NIDA-13444-3
• Secondary ID: R01-13444-3
• Status: Completed
• Phase: N/A
• First received: November 3, 2005
• Last updated: January 11, 2017
• Start date: August 2004
• Est. completion date: January 2006

Study information

• Verified date: May 2008
• Source: National Institute on Drug Abuse (NIDA)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of a lower-cost contingency management (CM) procedure in Hispanic substance abusing outpatients. Thirty individuals meeting DSM-IV criteria for substance dependence receive one of two conditions: (a) standard treatment, or (b) standard treatment plus prize CM. Using a cross-over design, CM is implemented in a community-based outpatient clinic and compared with non-CM in the same clinic. The participating clinic is randomly assigned to receive either the CM or non-CM phase first; 15 weeks after the final participant in one phase is enrolled, a one-week washout period occurs, followed by a switch to the other phase. Patients initiating outpatient treatment during the non-CM phase receive standard treatment and submit urine and breath samples 2/week during Weeks 1-6 and 1/week during Weeks 7-12. Patients initiating treatment during the CM phase also receive standard treatment and the same breath and urine monitoring. In addition, they earn the opportunity to win prizes for coming to treatment and for submitting negative breath and urine samples. Follow-up interviews are conducted at 1,3,6 and 9 months following intake during which substance use and psychosocial functioning are assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: January 2006
• Est. primary completion date: January 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• age > 18 years

• current DSM-IV substance dependence.

Exclusion criteria:

• have a serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk) on the basis of history or medical examination

• have dementia (<23 on the Mini Mental State Exam; Folstein et al. 1975)

• DSM-IV diagnosis of pathological gambling

• plans to move from the Hartford are within 9 months.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Substance Abuse
• Substance-Related Disorders

Intervention

Behavioral:
• Contingency management

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
National Institute on Drug Abuse (NIDA)	UConn Health

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Drug use		baseline and each follow-up	No